Abstract
T cell acute lymphoblastic leukemias (T-ALLs) arise from the malignant transformation of hematopoietic progenitors primed toward T cell development, as result of a multistep oncogenic process involving constitutive activation of NOTCH signaling and genetic alterations in transcription factors, signaling oncogenes, and tumor suppressors. Notably, these genetic alterations define distinct molecular groups of T-ALL with specific gene expression signatures and clinicobiological features. This review summarizes recent advances in our understanding of the molecular genetics of T-ALL.
MeSH terms
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / physiology
-
Cell Lineage
-
Cell Transformation, Neoplastic / genetics
-
Chromatin Assembly and Disassembly / genetics
-
Chromatin Assembly and Disassembly / physiology
-
Cyclin-Dependent Kinase Inhibitor p16 / physiology
-
Genes, p16
-
Hematopoietic Stem Cells / pathology
-
Homeodomain Proteins / genetics
-
Homeodomain Proteins / physiology
-
Humans
-
Molecular Targeted Therapy
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / physiology*
-
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / classification
-
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / etiology
-
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Prognosis
-
Receptors, Notch / physiology
-
Signal Transduction / genetics
-
Signal Transduction / physiology
-
T-Lymphocytes / pathology
-
Transcription Factors / physiology
-
Transcriptome
-
Tumor Suppressor Proteins / genetics
-
Tumor Suppressor Proteins / physiology
Substances
-
Cell Cycle Proteins
-
Cyclin-Dependent Kinase Inhibitor p16
-
Homeodomain Proteins
-
Neoplasm Proteins
-
Receptors, Notch
-
Transcription Factors
-
Tumor Suppressor Proteins